{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T19:59:01Z","timestamp":1771531141015,"version":"3.50.1"},"reference-count":26,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hepatic veno-occlusive disease (VOD) is a common complication of high-dose chemotherapy associated with bone marrow transplantation. While the pathogenesis of VOD is uncertain, plasminogen activator inhibitor-1 (PAI-1) has emerged as a diagnostic marker and predictor of VOD in humans. In this study, we investigated the role of PAI-1 in a murine model of VOD produced by long-term nitric oxide synthase inhibition using L-NAME. After 6 weeks, wild-type (WT) mice developed extensive fibrinoid hepatic venous thrombi and biochemical evidence of hepatic injury and dysfunction. In contrast, PAI-1\u2013deficient mice were largely protected from the development of hepatic vein thrombosis. Furthermore, WT mice that received tiplaxtinin, an antagonist of PAI-1, were effectively protected from L-NAME\u2013induced thrombosis. Taken together, these data indicate that NO and PAI-1 play pivotal and antagonistic roles in hepatic vein thrombosis and that PAI-1 is a potential target in the prevention and treatment of VOD in humans.<\/jats:p>","DOI":"10.1182\/blood-2005-07-2681","type":"journal-article","created":{"date-parts":[[2005,9,13]],"date-time":"2005-09-13T23:23:38Z","timestamp":1126653818000},"page":"132-134","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":47,"title":["Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis"],"prefix":"10.1182","volume":"107","author":[{"given":"Layton H.","family":"Smith","sequence":"first","affiliation":[{"name":"From the Departments of Medicine and Pathology, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN; and Wyeth Research, Collegeville, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Dixon","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine and Pathology, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN; and Wyeth Research, Collegeville, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Stringham","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine and Pathology, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN; and Wyeth Research, Collegeville, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mesut","family":"Eren","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine and Pathology, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN; and Wyeth Research, Collegeville, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Elokdah","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine and Pathology, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN; and Wyeth Research, Collegeville, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dave L.","family":"Crandall","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine and Pathology, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN; and Wyeth Research, Collegeville, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay","family":"Washington","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine and Pathology, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN; and Wyeth Research, Collegeville, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas E.","family":"Vaughan","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine and Pathology, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN; and Wyeth Research, Collegeville, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111703471328700_REF1","doi-asserted-by":"crossref","unstructured":"Richardson P, Guinan E. Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. Acta Haematologica. 2001;106: 57-68.","DOI":"10.1159\/000046590"},{"key":"2019111703471328700_REF2","unstructured":"Blostein MD, Paltiel OB, Thibault A, Rybka WB. A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation. Bone Marrow Transplant. 1992;10: 439-443."},{"key":"2019111703471328700_REF3","doi-asserted-by":"crossref","unstructured":"Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood. 1995;85: 3005-3020.","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005"},{"key":"2019111703471328700_REF4","doi-asserted-by":"crossref","unstructured":"Richardson P, Bearman SI. Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy. Leuk Lymphoma. 1998;31: 267-277.","DOI":"10.3109\/10428199809059219"},{"key":"2019111703471328700_REF5","doi-asserted-by":"crossref","unstructured":"Bearman SI, Lee JL, Baron AE, McDonald GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood. 1997;89: 1501-1506.","DOI":"10.1182\/blood.V89.5.1501"},{"key":"2019111703471328700_REF6","doi-asserted-by":"crossref","unstructured":"Falanga A, Vignoli A, Marchetti M, Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia. 2003;17: 1636-1642.","DOI":"10.1038\/sj.leu.2403004"},{"key":"2019111703471328700_REF7","unstructured":"DeLeve LD. Dacarbazine toxicity in murine liver cells: a model of hepatic endothelial injury and glutathione defense. J Pharmacol Exp Ther. 1994;268: 1261-1270."},{"key":"2019111703471328700_REF8","doi-asserted-by":"crossref","unstructured":"DeLeve LD. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology. 1996;24: 830-837.","DOI":"10.1002\/hep.510240414"},{"key":"2019111703471328700_REF9","doi-asserted-by":"crossref","unstructured":"DeLeve LD, Wang X, Kanel GC, et al. Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome. Hepatology. 2003;38: 900-908.","DOI":"10.1002\/hep.1840380416"},{"key":"2019111703471328700_REF10","unstructured":"Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43: 109-142."},{"key":"2019111703471328700_REF11","unstructured":"Kuroki I, Miyazaki T, Mizukami I, Matsumoto N, Matsumoto I. Effect of sodium nitroprusside on ischemia-reperfusion injuries of the rat liver. Hepatogastroenterology. 2004;51: 1404-1407."},{"key":"2019111703471328700_REF12","doi-asserted-by":"crossref","unstructured":"Bouchie JL, Hansen H, Feener EP. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells: role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol. 1998;18: 1771-1779.","DOI":"10.1161\/01.ATV.18.11.1771"},{"key":"2019111703471328700_REF13","unstructured":"Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb. 1989;9: 87-115."},{"key":"2019111703471328700_REF14","doi-asserted-by":"crossref","unstructured":"Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation. 1999;99: 3050-3055.","DOI":"10.1161\/01.CIR.99.23.3050"},{"key":"2019111703471328700_REF15","doi-asserted-by":"crossref","unstructured":"Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature. 1996;383: 441-443.","DOI":"10.1038\/383441a0"},{"key":"2019111703471328700_REF16","doi-asserted-by":"crossref","unstructured":"Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999;5: 1135-1142.","DOI":"10.1038\/13459"},{"key":"2019111703471328700_REF17","doi-asserted-by":"crossref","unstructured":"Olman MA, Mackman N, Gladson CL, Moser KM, Loskutoff DJ. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest. 1995;96: 1621-1630.","DOI":"10.1172\/JCI118201"},{"key":"2019111703471328700_REF18","doi-asserted-by":"crossref","unstructured":"Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int. 1997;51: 164-172.","DOI":"10.1038\/ki.1997.20"},{"key":"2019111703471328700_REF19","doi-asserted-by":"crossref","unstructured":"Kaikita K, Fogo AB, Ma L, Schoenhard JA, Brown NJ, Vaughan DE. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation. 2001;104: 839-844.","DOI":"10.1161\/hc3301.092803"},{"key":"2019111703471328700_REF20","doi-asserted-by":"crossref","unstructured":"Eren M, Painter CA, Atkinson JB, Declerck PJ, Vaughan DE. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation. 2002;106: 491-496.","DOI":"10.1161\/01.CIR.0000023186.60090.FB"},{"key":"2019111703471328700_REF21","doi-asserted-by":"crossref","unstructured":"Lee JH, Lee KH, Kim S, et al. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide. Br J Haematol. 2002;118: 1087-1094.","DOI":"10.1046\/j.1365-2141.2002.03748.x"},{"key":"2019111703471328700_REF22","doi-asserted-by":"crossref","unstructured":"Elokdah H, Abou-Gharbia M, Hennan JK, et al. Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. J Med Chem. 2004;47: 3491-3494.","DOI":"10.1021\/jm049766q"},{"key":"2019111703471328700_REF23","doi-asserted-by":"crossref","unstructured":"Carmeliet P, Kieckens L, Schoonjans L, et al. Plasminogen activator inhibitor-1 gene-deficient mice, I: generation by homologous recombination and characterization. J Clin Invest. 1993;92: 2746-2755.","DOI":"10.1172\/JCI116892"},{"key":"2019111703471328700_REF24","doi-asserted-by":"crossref","unstructured":"Hobbs AJ, Higgs A, Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. Annu Rev Pharmacol Toxicol. 1999;39: 191-220.","DOI":"10.1146\/annurev.pharmtox.39.1.191"},{"key":"2019111703471328700_REF25","doi-asserted-by":"crossref","unstructured":"Weisberg AD, Albornoz F, Griffin JP, et al. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II\/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol. 2005;25: 365-371.","DOI":"10.1161\/01.ATV.0000152356.85791.52"},{"key":"2019111703471328700_REF26","doi-asserted-by":"crossref","unstructured":"Ngo TH, Verheyen S, Knockaert I, Declerck PJ. Monoclonal antibody-based immunoassays for the specific quantitation of rat PAI-1 antigen and activity in biological samples. Thromb Haemost. 1998;79: 808-812.","DOI":"10.1055\/s-0037-1615069"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/1\/132\/1279497\/zh800106000132.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/1\/132\/1279497\/zh800106000132.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T03:47:28Z","timestamp":1573962448000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/1\/132\/21753\/Pivotal-role-of-PAI1-in-a-murine-model-of-hepatic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-07-2681","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,1]]}}}